Tilray Medical, a division of Tilray Brands, Inc., has achieved a historic milestone by becoming the first company to receive authorization from the Italian Ministry of Health to distribute medical cannabis in Italy. This approval allows Tilray to import and sell its proprietary cannabis flower products for therapeutic use across the country.
Effective June 2025, three new cannabis flower varieties will be available in Italian pharmacies: – Tilray THC 25% – Tilray THC 18% – Tilray THC 9% / CBD 9%
Denise Faltischek, Chief Strategy Officer at Tilray Brands, highlighted the importance of this development for patients seeking medical cannabis. She emphasized the commitment to providing high-quality, EU-GMP certified products that meet stringent safety and reliability standards.
Tilray’s entry into the Italian market reflects its ongoing expansion in Europe, where it operates in several countries including Germany, Portugal, and Poland. The company aims to establish itself as a leading supplier of medical cannabis, offering a diverse portfolio of products designed to meet patient needs.
With the medical cannabis market in Italy valued at approximately $2 billion, Tilray’s approval positions it strategically to cater to the growing demand for cannabinoid-based therapies. This initiative not only enhances patient access to medical cannabis but also supports the evolving landscape of therapeutic options available in Italy.
Tilray Medical has a robust history, originating as one of the first licensed producers of medical cannabis in Canada. The company continues to focus on expanding its global reach while adhering to regulatory frameworks that ensure safe access to its products.
For more information about Tilray Medical’s offerings and the implications of this new development in Italy, please visit their official website.
Czech 
English 
Spanish 
German